Deep Track Capital LP acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,000,000 shares of the company's stock, valued at approximately $16,440,000. Deep Track Capital LP owned approximately 1.87% of Upstream Bio as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $117,977,000. Decheng Capital LLC acquired a new stake in Upstream Bio in the 4th quarter worth $54,010,000. TCG Crossover Management LLC bought a new position in shares of Upstream Bio during the 4th quarter worth about $44,856,000. Bain Capital Life Sciences Investors LLC acquired a new stake in Upstream Bio during the fourth quarter worth about $37,735,000. Finally, Samsara BioCapital LLC bought a new position in Upstream Bio during the fourth quarter valued at about $36,450,000.
Upstream Bio Price Performance
Shares of NASDAQ:UPB traded down $0.11 during trading on Friday, hitting $8.73. 324,835 shares of the stock were exchanged, compared to its average volume of 328,210. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46. The company's fifty day simple moving average is $8.03 and its 200-day simple moving average is $13.58.
Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Sell-side analysts predict that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
